{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-274553","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.603438+00:00","generated_at":"2026-06-22T17:00:58.835231+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edwards Lifesciences announces $750M accelerated share repurchase, initial ~8M shares","bullets":["$750M ASR executed; initial delivery of ~8M shares, remainder based on VWAP over term.","Total 2022 repurchases exceed $1.7 billion.","Approximately $900 million remains in board-authorized repurchase plan.","Repurchase funded with existing cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-274553","json":"https://secwatch.observer/filing/0001193125-22-274553.json","markdown":"https://secwatch.observer/filing/0001193125-22-274553.md","text":"https://secwatch.observer/filing/0001193125-22-274553.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522274553/0001193125-22-274553-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522274553/d414194d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T17:00:58.835231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}